193 related articles for article (PubMed ID: 10454198)
21. Tyrosine kinase inhibitors in preclinical development.
Levitt ML; Koty PP
Invest New Drugs; 1999; 17(3):213-26. PubMed ID: 10665475
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
23. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
Ciardiello F
Drugs; 2000; 60 Suppl 1():25-32; discussion 41-2. PubMed ID: 11129169
[TBL] [Abstract][Full Text] [Related]
25. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
26. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
28. The role of EGFR-directed therapy in the treatment of breast cancer.
Morris C
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S51-5; discussion S57-9. PubMed ID: 12353824
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.
Baguley BC; Marshall ES; Holdaway KM; Rewcastle GW; Denny WA
Eur J Cancer; 1998 Jun; 34(7):1086-90. PubMed ID: 9849459
[TBL] [Abstract][Full Text] [Related]
30. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
31. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase.
Lee JY; Park YK; Seo SH; So IS; Chung HK; Yang BS; Lee SJ; Park H; Lee YS
Arch Pharm (Weinheim); 2001 Nov; 334(11):357-60. PubMed ID: 11822173
[TBL] [Abstract][Full Text] [Related]
32. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor as a target for anti-cancer agent design.
Cao J; Fang H; Wang B; Ma C; Xu W
Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.
Mu F; Coffing SL; Riese DJ; Geahlen RL; Verdier-Pinard P; Hamel TE; Johnson J; Cushman M
J Med Chem; 2001 Feb; 44(3):441-52. PubMed ID: 11462983
[TBL] [Abstract][Full Text] [Related]
35. Molecular target-based cancer therapy: tyrosine kinase inhibitors.
Tamura K; Fukuoka M
Int J Clin Oncol; 2003 Aug; 8(4):207-11. PubMed ID: 12955575
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule tyrosine kinase inhibitors as radiosensitizers.
Lawrence TS; Nyati MK
Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):33-6. PubMed ID: 12174343
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tyrosine kinase activity decreases expression of surfactant protein A in a human lung adenocarcinoma cell line independent of epidermal growth factor receptor.
Klein JM; McCarthy TA
Biochim Biophys Acta; 1997 Mar; 1355(3):218-30. PubMed ID: 9060993
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Bunn PA; Franklin W
Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
[TBL] [Abstract][Full Text] [Related]
40. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
